Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$106.27
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | GILD Avg Daily Volume: 12,040,700
Last Update: 08/26/14 - 4:00 PM EDT
Volume: 0
YTD Performance: 41.50%
Open: $0.00
Previous Close: $106.27
52 Week Range: $58.50 - $108.72
Oustanding Shares: 1,511,670,456
Market Cap: 162,428,990,497
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 15 15
Moderate Buy 1 1 1 2
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.33 1.28 1.32
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 24.20
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
24.20 24.10 28.88
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
31.29% 75.89% 448.77%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 121.60 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.64 $2.22 $7.26 $9.07
Number of Analysts 3 3 3 3
High Estimate $1.85 $2.81 $8.34 $10.13
Low Estimate $1.35 $1.52 $5.51 $7.31
Prior Year $0.50 $0.52 $1.92 $7.26
Growth Rate (Year over Year) 227.33% 326.28% 278.30% 24.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
The Burger King deal exemplifies companies helping themselves and the index.

Best Ideas Update Real Money Pro($)

For accountability's sake, here is an update on my on my current five best ideas.
There has been huge progress in treating this lethal disease.
Bullish
Aug 15, 2014 | 7:22 AM EDT
GILD was initiated with an Outperform rating, FBR Capital Markets said. $125 price target. Hepatitis C market has net been fully apprec...
Biotech stocks are thriving in a slower-growth, low-inflation world.

Gilead Is Thorny, Short Term Real Money Pro($)

The quick and dirty on Gilead Sciences.

Never Trade Outside Hours Real Money Pro($)

Pace yourself for a marathon, don't try to beat others in a sprint.
These quality names look appealing on the basis of 30-week moving average.

Rally Into the Close Real Money Pro($)

We'll see.

About That Shopping List Real Money Pro($)

Apple and Gilead Sciences are on it.

Columnist Conversations

Paul - The BRLI looks like just a bad 100 share trade out of over 10,000 shares traded. I would put no weight ...
Sometimes we just want to look at charts... this will be the first in a series of just that. Today we observe...
Laboratory testing company Bio-Reference Labs (BRLI) was up 5.66%, at $33.58, as of 5:37 PM. EPS are due out ...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.